GlassScriptPhysician profile
Rizwan Akhtar
NPI 1669695649
$6,768.91
in general payments reported to CMS, 2019-2025
32 companies · $1,865 in 2025
The $1,865 reported for 2025 was more than what 89% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $566 · 2020: $112 · 2021: $580 · 2022: $974 · 2023: $1,094 · 2024: $1,577 · 2025: $1,865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,287 · Education: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,287.41 |
| Education | $248.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $1,314.96 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Amgen INC. | $965.28 | 2019-2025 | Krystexxa, Tavneos, Uplizna |
| Astrazeneca Pharmaceuticals LP | $638.64 | 2019-2025 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $508.22 | 2019-2025 | Rayaldee |
| Vifor Pharma, INC. | $401.38 | 2021-2025 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $400.62 | 2019-2025 | Jynarque, Voyxact |
| Travere Therapeutics, INC. | $313.76 | 2023-2025 | Thiola |
| Bayer Healthcare Pharmaceuticals INC. | $301.89 | 2021-2025 | |
| Lilly USA, LLC | $272.17 | 2023-2025 | Jardiance |
| Ardelyx, INC. | $174.09 | 2024-2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $161.84 | 2019-2025 | |
| Daiichi Sankyo INC. | $156.47 | 2019-2024 | Injectafer |
| Aurinia Pharma U.S., INC. | $139.83 | 2022-2025 | Lupkynis |
| Calliditas Therapeutics US INC. | $137.52 | 2022-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $121.15 | 2019-2023 | Krystexxa, Procysbi |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $96.99 | 2020-2024 | Terlivaz |
| Glaxosmithkline, LLC. | $91.38 | 2020-2025 | Arexvy, Shingrix |
| Nxstage Medical, INC. | $90.39 | 2019-2025 | Liberty Select Cycler, Nxstage System One |
| Genzyme Corporation | $69.21 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.40 | 2023-2025 | Gattex |
| Amag Pharmaceuticals, INC. | $63.31 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $44.30 | 2022 | |
| Apellis Pharmaceuticals, INC. | $43.31 | 2025 | Empaveli |
| Chiesi USA, INC. | $39.20 | 2024 | Elfabrio |
| Shield Therapeutics INC | $22.32 | 2022 | |
| Renalytix Ai, INC. | $21.07 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Ascendis Pharma Endocrinology INC | $20.87 | 2025 | Yorvipath |
| Mallinckrodt Enterprises LLC | $20.05 | 2019 | |
| Kyowa Kirin, INC. | $19.91 | 2025 | |
| Ani Pharmaceuticals, INC. | $18.55 | 2023 | Purified Cortrophin Gel |
| Akebia Therapeutics INC | $17.20 | 2021 | |
| Covidien LP | $16.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rizwan Akhtar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.